Free tool
FAERS Monitor: Coreg Cr
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022012 or its brand name (Coreg Cr, Carvedilol Phosphate). Reports on generic versions are filed under their own applications.
Reports
2,975
Serious
1,127
38% of reports
Hospitalization
590
Death reported
148
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness309
- fatigue298
- drug ineffective291
- dyspnoea192
- nausea145
- headache142
- blood pressure increased139
- diarrhoea131
- hypotension121
- asthenia109
- malaise104
- fall92
- weight increased85
- death76
- feeling abnormal75
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 499 |
| 2008 | 443 |
| 2009 | 305 |
| 2010 | 155 |
| 2011 | 162 |
| 2012 | 126 |
| 2013 | 145 |
| 2014 | 210 |
| 2015 | 196 |
| 2016 | 162 |
| 2017 | 124 |
| 2018 | 100 |
| 2019 | 112 |
| 2020 | 67 |
| 2021 | 34 |
| 2022 | 32 |
| 2023 | 19 |
| 2024 | 30 |
| 2025 | 34 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,184 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 139 | 6.4 | 5.5 | 636 |
| dizzinessSignal | 309 | 4.4 | 3.9 | 822 |
| hypotensionSignal | 121 | 4.3 | 3.6 | 302 |
| fatigueSignal | 298 | 2.7 | 2.4 | 331 |
| weight increasedSignal | 85 | 2.7 | 2.2 | 89 |
| dyspnoeaSignal | 192 | 2.4 | 2.1 | 159 |
| feeling abnormalSignal | 75 | 2.2 | 1.8 | 49 |
| astheniaSignal | 109 | 2.0 | 1.7 | 59 |
| fall | 92 | 2.0 | 1.6 | 43 |
| malaise | 104 | 1.7 | 1.4 | 28 |
| headache | 142 | 1.6 | 1.4 | 32 |
| drug ineffective | 291 | 1.6 | 1.4 | 62 |
| diarrhoea | 131 | 1.4 | 1.2 | 17 |
| nausea | 145 | 1.3 | 1.1 | 10 |
| death | 76 | 0.6 | 0.5 | 18 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.